Ocular Therapeutix, Inc.

Ocular Therapeutix, Inc. is a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for diseases and conditions of the eye. The company utilizes its proprietary bioresorbable hydrogel-based formulation technology, ELUTYX, to create sustained-release drug delivery platforms. Headquartered in Bedford, Massachusetts, Ocular Therapeutix aims to redefine the retina experience through its advanced ophthalmic solutions. [2, 3, 9, 10, 11, 12, 17, 20, 21, 26, 27, 29, 31, 32, 35, 36, 37, 38]

Key commercial products include DEXTENZA, a dexamethasone ophthalmic insert approved for post-surgical ocular inflammation and pain, as well as ocular itching associated with allergic conjunctivitis. The company also markets ReSure Sealant, a synthetic hydrogel for sealing corneal incisions. Its robust pipeline features AXPAXLI (also known as OTX-TKI), an investigational axitinib intravitreal hydrogel in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD) and diabetic retinal disease, and PAXTRAVA (also known as OTX-TIC), a travoprost intracameral hydrogel for open-angle glaucoma or ocular hypertension. [2, 3, 8, 10, 11, 12, 13, 14, 15, 18, 20, 22, 26, 27, 29, 31, 33, 38]

In April 2024, Pravin U. Dugel, MD, was appointed President and Chief Executive Officer, while also continuing his role as Executive Chairman. [4, 5, 6, 29, 35] Ocular Therapeutix recently initiated the SOL-X long-term extension trial for AXPAXLI in wet AMD, building on positive results from the SOL-1 trial. [15, 16, 23, 24, 39] The company is actively preparing a New Drug Application (NDA) for AXPAXLI, with discussions underway with the FDA regarding a potential single pivotal trial filing and patent coverage extending to 2044, positioning Ocular Therapeutix to become a significant player in retina care. [6, 16]